1. Narimatsu H. Development of M2BPGi: a novel fibrosis serum glycobiomarker for chronic hepatitis/cirrhosis diagnostics. Expert Rev Proteomics. 2015; 12:683–693. PMID:
26394846.
2. Cho SY, Lee HJ, Kim JW, Park TS. Mean platelet volume and mean platelet volume/platelet count ratio in patients with chronic alcohol consumption. Platelets. 2015; 26:371–372. PMID:
24617309.
3. Moon HW, Park M, Hur M, Kim H, Choe WH, Yun YM. Usefulness of enhanced liver fibrosis, glycosylation isomer of Mac-2 binding protein, galectin-3, and soluble suppression of tumorigenicity 2 for assessing liver fibrosis in chronic liver diseases. Ann Lab Med. 2018; 38:331–337. PMID:
29611383.
4. Lambrecht J, Verhulst S, Mannaerts I, Reynaert H, van Grunsven LA. Prospects in non-invasive assessment of liver fibrosis: liquid biopsy as the future gold standard. Biochim Biophys Acta. 2018; 1864:1024–1036. PMID:
29329986.
5. Shirabe K, Bekki Y, Gantumur D, Araki K, Ishii N, Kuno A, et al. Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis. J Gastroenterol. 2018; 1. 09. DOI:
10.1007/s00535-017-1425-z. [Epub ahead of print].
6. Atsukawa M, Tsubota A, Okubo T, Arai T, Nakagawa A, Itokawa N, et al. Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein more reliably distinguishes liver fibrosis stages in non-alcoholic fatty liver disease than serum Mac-2 binding protein. Hepatol Res. 2017; 12. 23. DOI:
10.1111/hepr.13046. [Epub ahead of print].
7. Jekarl DW, Choi H, Lee S, Kwon JH, Lee SW, Yu H, et al. Diagnosis of liver fibrosis with Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA-M2BP) among chronic hepatitis B patients. Ann Lab Med. 2018; 38:348–354. PMID:
29611385.